818 / 1835
Summary
•
With longer follow-up, nivolumab in cHL resulted in :
–
Durable CRs and PRs
–
Consistent and manageable adverse event profile
•
Long-term therapy (up to 2 yr) appears feasible
•
Durable responses and encouraging PFS and OS
•
These data support the further investigation of nivolumab in patients with
cHL in a larger, ongoing phase 2 study, CHECKMATE 205
37